NeuroSense Therapeutics Ltd. Ordinary Shares (NRSN)
Stock · NASDAQ · Health Care
$3.07as of 10/16/2026
Price chart
Active signals
NRSN Signal Track Record
How signals performed across all stocks →What NRSN's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 42 | -5.7% | 38% | September 4, 2026 |
| Bollinger Band Breakout | 17 | -3.4% | 35% | September 4, 2026 |
| Bollinger Band Breakdown | 15 | -5.5% | 33% | July 22, 2026 |
| 200-Day Moving Average TouchActive now | 15 | -1.4% | 40% | May 5, 2025 |
| Any 20-session window (baseline) | -4.0% | 41% |
Computed by MarketWall from daily closing prices since September 26, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About NRSN
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyot…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 17
- Website
- www.neurosense-tx.com/
Fundamentals
- 1-day range
- $2.87$3.26
- Market cap
- $19.00M
- P/E (trailing)
- —
- P/E (forward)
- -0.68
- EPS (trailing)
- $-10.79
- Dividend yield
- —
- Beta
- 1.63
- Avg. volume
- 22.8K
Forecasts
3 analyst ratings
NeuroSense Therapeutics Ltd. Ordinary Shares Competitors
Chosen by industry and closest market cap.
- NRSNNeuroSense Therapeutics Ltd. Ordinary Shares$3.07▼ 3.15%Market cap $19.00MP/E —$3.05$26.64
- MRKRMarker Therapeutics Inc. Common Stock$1.04▲ 13.04%Market cap $18.67MP/E —$0.84$2.46
- HOWLWerewolf Therapeutics Inc. Common Stock$0.98▼ 1.71%Market cap $19.58MP/E —$0.27$2.24
- RKTORocket One Inc. Common Stock$0.507▼ 5.59%Market cap $19.75MP/E —$0.51$2.45
- CELUCelularity Inc. Class A Common Stock$1.25▼ 6.02%Market cap $19.77MP/E —$0.5601$2.55
- GRDXGridAI Technologies Corp. Common Stock$4.22▼ 5.38%Market cap $19.91MP/E —$1.87$6.93
- DAREDare Bioscience Inc. Common Stock$0.725▼ 2.03%Market cap $19.92MP/E —$0.69$3.78
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| NRSN NeuroSense Therapeutics Ltd. Ordinary Shares | $19.00M | — | $3.07 | ▼ 3.15% | $3.05$26.64 |
| MRKR Marker Therapeutics Inc. Common Stock | $18.67M | — | $1.04 | ▲ 13.04% | $0.84$2.46 |
| HOWL Werewolf Therapeutics Inc. Common Stock | $19.58M | — | $0.98 | ▼ 1.71% | $0.27$2.24 |
| RKTO Rocket One Inc. Common Stock | $19.75M | — | $0.507 | ▼ 5.59% | $0.51$2.45 |
| CELU Celularity Inc. Class A Common Stock | $19.77M | — | $1.25 | ▼ 6.02% | $0.5601$2.55 |
| GRDX GridAI Technologies Corp. Common Stock | $19.91M | — | $4.22 | ▼ 5.38% | $1.87$6.93 |
| DARE Dare Bioscience Inc. Common Stock | $19.92M | — | $0.725 | ▼ 2.03% | $0.69$3.78 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- SpaceX, Qualcomm and 3 Stocks to Watch Heading Into Mondaybenzinga · 10/5/2026
- SpaceX, Qualcomm and 3 Stocks to Watch Heading Into MondayBenzinga · 10/5/2026
- NeuroSense Provides Update on Nasdaq Listing ComplianceYahoo · 10/2/2026
- NeuroSense Therapeutics Receives Nasdaq Noncompliance Notice; Co. Plans To AppealBenzinga · 10/2/2026
- NeuroSense to Participate in the 5th Annual ROTH Healthcare Opportunities ConferenceYahoo · 9/28/2026
- HC Wainwright & Co. Maintains Buy on NeuroSense Therapeutics, Raises Price Target to $52Benzinga · 9/28/2026
- NeuroSense Provides Business Update and Progress for the First Half of 2026Yahoo · 9/25/2026
- NeuroSense Therapeutics H1 EPS $(2.10) up From $(3.70) YoYBenzinga · 9/25/2026
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
NeuroSense Reports Improved H1 Losses and Raises Price Target
NeuroSense Therapeutics reported a narrower net loss for the first half of 2026, with EPS improving to negative $2.10 from negative $3.70 a year ago. The company also announced it will speak at the ROTH Healthcare Opportunities Conference. Meanwhile, HC Wainwright raised its price target to $52, reflecting a positive view on the company's progress.
NeuroSense Reports Improved H1 Losses and Raises Price Target. NeuroSense Therapeutics reported a narrower net loss for the first half of 2026, with EPS improving to negative $2.10 from negative $3.70 a year ago. The company also announced it will speak at the ROTH Healthcare Opportunities Conference. Meanwhile, HC Wainwright raised its price target to $52, reflecting a positive view on the company's progress.